Short Interest in Exicure, Inc. (NASDAQ:XCUR) Declines By 19.8%

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a significant drop in short interest during the month of April. As of April 15th, there was short interest totalling 27,500 shares, a drop of 19.8% from the March 31st total of 34,300 shares. Approximately 3.3% of the shares of the company are short sold. Based on an average daily volume of 41,100 shares, the days-to-cover ratio is presently 0.7 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Exicure stock. Carlyle Group Inc. grew its holdings in shares of Exicure, Inc. (NASDAQ:XCUR) by 400.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 281,636 shares of the company’s stock after purchasing an additional 225,308 shares during the quarter. Exicure makes up about 0.9% of Carlyle Group Inc.’s portfolio, making the stock its 11th biggest holding. Carlyle Group Inc. owned approximately 10.79% of Exicure worth $3,850,000 at the end of the most recent quarter. 42.82% of the stock is currently owned by hedge funds and other institutional investors.

Exicure Trading Up 7.6 %

XCUR opened at $10.73 on Friday. The firm has a 50 day moving average of $11.65 and a two-hundred day moving average of $11.54. The firm has a market capitalization of $67.79 million, a PE ratio of -5.18 and a beta of 3.74. Exicure has a 12-month low of $1.44 and a 12-month high of $36.00.

Exicure (NASDAQ:XCUR) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($3.39) EPS for the quarter.

About Exicure

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.